MiR-138-5p Suppresses Cell Growth and Migration in Melanoma by Targeting Telomerase Reverse Transcriptase
Recent evidence suggests the existence of a miRNA regulatory network involving human telomerase reverse transcriptase gene ( ), with miR-138-5p playing a central role in many types of cancers. However, little is known about the regulation of expression by microRNA (miRNAs) in melanocytic tumors. Her...
Saved in:
Published in | Genes Vol. 12; no. 12; p. 1931 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
30.11.2021
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Recent evidence suggests the existence of a miRNA regulatory network involving human telomerase reverse transcriptase gene (
), with miR-138-5p playing a central role in many types of cancers. However, little is known about the regulation of
expression by microRNA (miRNAs) in melanocytic tumors. Here, we investigated the effects of miR-138-5p in
regulation in melanoma cells lines. In vitro studies demonstrated higher miR-138-5p and lower
messenger RNA (mRNA) expression in human epidermal melanocytes, compared with melanoma cell lines (A2058, A375, SK-MEL-28) by quantitative polymerase chain reaction (qPCR) observing a negative correlation between them. A2058 melanoma cells were selected to be transfected with miR-138-5p mimic or inhibitor. Using luciferase assay,
was identified as a direct target of this miRNA. Overexpression of miR-138-5p detected by Western blot revealed a decrease in hTERT protein expression (
= 0.012), and qPCR showed a reduction in telomerase activity (
< 0.001). Moreover, suppressions in cell growth (
= 0.035) and migration abilities (
= 0.015) were observed in A2058-transfected cells using thiazolyl blue tetrazolium bromide and flow cytometry, respectively. This study identifies miR-138-5p as a crucial tumor suppressor miRNA involved in telomerase regulation. Targeting it as a combination therapy with immunotherapy or targeted therapies could be used in advanced melanoma treatment; however, more preclinical studies are necessary. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. |
ISSN: | 2073-4425 2073-4425 |
DOI: | 10.3390/genes12121931 |